Clinical Focus

• Cardiac Electrophysiology
• Cardiology (Heart)
• Atrial Fibrillation
• Cardiac Arrhythmias
• Implantable Defibrillators

Professional Education

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information

Current Research Interests

Dr. Wang's research centers on the development of innovative approaches to the treatment of arrhythmias, including more effective catheter ablation techniques, more reliable implantable devices, and less invasive treatments. Dr. Wang's clinical research interests include atrial fibrillation, ventricular tachycardia, syncope, and hypertrophic cardiomyopathy. Dr. Wang has active collaborations with Bioengineering, Mechanical Engineering, and Electrical Engineering Departments at Stanford. Some of the goals of his research program are: 1) to create a more effective methods of catheter ablation, 2) to create implantable pacemakers and leads that are more reliable, 3) to create a combined surgical-catheter approach to ablation, 4) to create noninvasive methods of ablation, 5) to make defibrillation painless.

Clinical Trials

• Catheter ABlation Versus Antiarrhythmic Drug Therapy For Atrial Fibrillation Trial (CABANA) Recruiting
• A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation No longer recruiting
• To assess the safety and technical feasibility of treating subjects with Persistent Atrial Fibrillation or Longstanding Persistent Atrial Fibrillation using a hybrid approach of epicardial and endocardial ablation. No longer recruiting

Publications

• A novel method for patient-specific QTc--modeling QT-RR hysteresis. Hadley DM, Froelicher VF, Wang PJ. Ann Noninvasive Electrocardiol. 2011; 16 (1): 3-12
• Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP. Ann Intern Med. 2011; 154 (1): 1-11
• Cost-effectiveness of genetic testing in family members of patients with long-QT syndrome. Perez MV, Kumarasamy NA, Owens DK, Wang PJ, Hlatky MA. Circ Cardiovasc Qual Outcomes. 2011; 4 (1): 76-84
• Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Zareba W, Klein H, Cygankiewicz I, Hall WJ, McNitt S, Brown M, Cannom D, Daubert JP, Eldar M, Gold MR, Goldberger JJ, Goldenberg I, Lichstein E, Pitschner H, Rashtian M, Solomon S, Viskin S, Wang P, Moss AJ. Circulation. 2011; 123 (10): 1061-72
• Subcutaneous implantable cardioverter-defibrillator technology. Gupta A, Al-Ahmad A, Wang PJ. Heart Fail Clin. 2011; 7 (2): 287-94, x